The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market’s growth. • By product segment, the drugs segment accounted for the largest share of human microbiome market:
Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. Drugs segment accounted for the largest product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs
By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period. Based on application, the human microbiome market is segmented into therapeutics and diagnostics.The diagnostics segment is expected to grow at the highest CAGR during the forecast period.
Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.
By genomic technologies, the sequencing segment is expected to grow at the highest CAGR during the forecast period. Based on technology, the human microbiome market is further segmented into sequencing and other genomic technologies {PCR, microarray, and fluorescent in situ hybridization (FISH)}. The availability of advanced, efficient, and accurate next-generation sequencing systems at a low cost, along with the reduced cost of sequencing, has greatly boosted the adoption of the latest sequencing technologies in the human microbiome market North America: The largest region in the human microbiome market. In the human microbiome market, North America is estimated to maintain its vanguard during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.
Breakdown of primaries The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows: •?By Designation: Managers: 55%, Executives: 25%, and CXOs: 20%, •?By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10% Prominent players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), OptiBiotix Health (UK), Synlogic (US), International flavors & Fragrances (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).
Research Coverage: The report segments the human microbiome market based on region (Asia Pacific, Europe, North America, and RoW), product (prebiotics, probiotics, drugs, diagnostic tests, and other products), technology (Genomics, Proteomics, and Metabolomics), application (therapeutics and diagnostics), disease (hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users). The report also provides a comprehensive review of market drivers, opportunities, restraints, and challenges in the human microbiome market. .
Key Benefits of Buying the Report: The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments.This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.
The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
The global rehabilitation equipment market is projected to reach USD 19.8 billion by 2027 from USD 14.9 billion in 2022, at a CAGR of 5.9% during the forecast period. Increasing geriatric population and obese populations, increasing chronic diseases, high risk of injuries to caregivers during the manual handling of patients, and increasing...
248 pages •
By The Business Research Company
• Jun 2022
Research Antibodies And Reagents Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global research antibodies and reagents market as it emerges from the COVID 19 shut down. Description: Where...
This study considers a detailed scenario of the present medical ventilators market and its market dynamics for 2022?2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent...
The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period. Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages...
The global depth of anesthesia monitoring market is projected to reach US$ 280.83 million by 2028 from US$ 203.32 million in 2021; it is expected to grow at a CAGR of 4.7% from 2021 to 2028. The rising number of surgical procedures drives the overall growth of the depth of anesthesia monitoring market. However, the high maintenance cost of...
The exosome research market is valued at an estimated USD 144 million in 2021 and is projected to reach USD 661 million by 2026, at a CAGR of 35.6% during the forecast period, owing to increased funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. By...
Global Oncology Precision Medicine Market to Reach $1,28,891.6 Million by 2031 Market Report Coverage - Oncology Precision Medicine Market Segmentation • Ecosystem - Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics • Application...
The autotransfusion devices market is expected to grow from US$ 1,000.26 million in 2021 to US$ 1,331.99 million by 2028; it is estimated to grow at a CAGR of 4.2% from 2021 to 2028. Rapid increase in chronic diseases, rise in transplants, and difficulty in obtaining blood groups across the globe are driving the growth of the market....
The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high...
Oncology information systems manage data from various treatment schedules, treatment plans, and treatment delivery for each patient.Focus on laying a framework on standardization in OIS is further advancing the level of care for each cancer patient through a multidisciplinary approach. Factors such as increasing adoption of OIS solutions...
Healthcare
Patient Data Management
Oncology
Oncology
United States
World
North America
Europe
APAC
Medical Technology Density
Cancer Incidence
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.